VivaChek Blood Glucose and ß-Ketone Dual BLE Monitoring System;VivaChek Blood Glucose and ß-Ketone Dual Monitoring System.
Vivachek Biotech (Hangzhou) Co., Ltd. · Decision date Oct 9, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 10/09/2026 for VivaChek Blood Glucose and ß-Ketone Dual BLE Monitoring System;VivaChek Blood Glucose and ß-Ketone Dual Monitoring System., submitted by Vivachek Biotech (Hangzhou) Co., Ltd. of Hangzhou, CN, under 510(k) number K260687. The application was received 03/03/2026 and reviewed under regulation 862.1345 in the Clinical Chemistry specialty, with classification product code NBW and subsequent product code JIN. SESE in this context is a 510(k) clearance, not a premarket approval.
The record describes a traditional 510(k) that was not reviewed by a third party, was not a combination product, and had no authorized predetermined change control plan. A separate FDA over-the-counter listing for the same document number gives an effective date of 10/13/2026 and describes the test type as glucose monitoring devices cleared for home use. The source does not include the decision summary, performance data, or the specific technological differences from the predicate device.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260687
- Regulatory pathway
- 510(k) premarket notification
- Product code
- NBW
- Decision code
- SESE
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Blood Glucose, Over The Counter.
- Product code
- NBW
- FDA device class
- 2
FDA decision timeline
K260687 received
Application receipt date recorded by FDA.
K260687 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Changsha Sinocare, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
| EPS Bio Technology Corp. | 510(k) clearance | Oct 23, 2026 | FDA | |
| I-Sens, Inc. | 510(k) clearance | Oct 2, 2026 | FDA | |
| Ascensia Diabetes Care | 510(k) clearance | Aug 27, 2026 | FDA | |
| Trividia Health, Inc. | 510(k) clearance | Jul 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vivachek Biotech (Hangzhou) Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hangzhou
Sources and methodology
- Original FDA record: K260687
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


